Clexane® in arthroscopic surgery - CLASS. Primary prevention of thromboembolic events in arthroscopic surgery at the knee - A multicenter postmarketing survey;Clexane® in arthroscopic surgery - CLASS. Primärprävention thromboembolischer ereignisse mit Clexane® bei arthroskopischen eingriffen am knie - Eine multizentrische anwendungsbeobachtung

Aktuelle Traumatologie

Volumn 36, Issue 4, 2006, Pages 166-170

  Friebe, Holger ^a   Peters, A ^b  

^a Reha Zentrum Wiesbaden   (Germany)

^b Schwarzwaldklinik Orthopadie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ARTHROSCOPIC SURGERY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEMARTHROSIS; HEMATOMA; HUMAN; KNEE; LUNG EMBOLISM; PREVALENCE; PROPHYLAXIS; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

EID: 33749589753     PISSN: 00446173     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924587     Document Type: Review

References (19)

1. Bergquist D et al. Low-molecular-weight heparin (Enoxiparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 695-700
2. Delis KT. Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy. Thromb Haemost 2001; 86: 817-821
3. Demers C et al. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998; 158: 47-50
4. Deutsches Arzneimittelgesetz § 67.6
5. Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm 2001; 58 (Suppl 2): S4-S13
6. Encke A et al. Stationäre und ambulante Thromboembolie-Prophylaxe in der Chirurgie und der perioperativen Medizin. Beilage zu den Mitteilungen der Deutschen Gesellschaft für Chirurgie, Heft 3/2003
7. Michot M et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomized trial of prophylaxis with low-molecular weight heparin. Arthroscopy 2002; 18: 257-263
8. Middecke M. Nicht nur beobachten, auch publizieren. Dtsch Med Wschr 2003; 128: 857-888
9. Muntz JE. The risk of venous thromboembolism in non-large-joint surgeries. Orthopedics 2003; 26: 237-242
10. Nerurkar J, Wade WE, Martin BC. Cost/Death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Pharmacotherapy 2002; 22: 990-1000
11. Patsch H, Blättler W. Leitlinien zur Thrombose-Prophylaxe. Phlebol 1996; 25: 261-266
12. Pauschert R, Diehm C, Stammler F. Leitlinien der DGOT. Z Orthopädie 1998; 136: 471-479
13. Petersen JL et al. Efficacy and bleeding complications among patients randomized to Enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. JAMA 2004; 292: 89-96
14. Schippinger G et al. Thromboembolic complications after arthroscopic knee surgery. Acta Orthop Scand 1998; 69: 144-146
15. Turpie AGG et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
16. Warkentin TE et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335
17. Wirth T et el. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin). Results of a randomized controlled trial. Arthroscopy 2001; 17: 393-399
18. Witt M. Heparin nach Kniegelenkarthroskopie. Dtsch Med Wschr 2000; 125: 1059
19. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256